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Contraceptive Hormone Use and Cardiovascular Disease
Chrisandra L. Shufelt, MD, MS, C. Noel Bairey Merz, MD, FACC
Los Angeles, California
Contraceptive hormones, most commonly prescribed as oral contraceptives (OCs), are a widely utilized method
to prevent ovulation, implantation, and, therefore, pregnancy. The Women’s Health Initiative demonstrated car-
diovascular risk linked to menopausal hormone therapy among women without pre-existing cardiovascular dis-
ease, prompting a review of the safety, efficacy, and side effects of other forms of hormone therapy. A variety of
basic science, animal, and human data suggests that contraceptive hormones have antiatheromatous effects;
however, relatively less is known regarding the impact on atherosclerosis, thrombosis, vasomotion, and arrhyth-
mogenesis. Newer generation OC formulations in use indicate no increased myocardial infarction risk for current
users, but a persistent increased risk of venous thromboembolism. There are no cardiovascular data available
for the newest generation contraceptive hormone formulations, including those that contain newer progestins
that lower blood pressure, as well as the nonoral routes (transdermal and vaginal). Current guidelines indicate
that, as with all medication, contraceptive hormones should be selected and initiated by weighing risks and ben-
efits for the individual patient. Women 35 years and older should be assessed for cardiovascular risk factors
including hypertension, smoking, diabetes, nephropathy, and other vascular diseases, including migraines, prior
to use. Existing data are mixed with regard to possible protection from OCs for atherosclerosis and cardiovascu-
lar events; longer-term cardiovascular follow-up of menopausal women with regard to prior OC use, including
subgroup information regarding adequacy of ovulatory cycling, the presence of hyperandrogenic conditions, and
the presence of prothrombotic genetic disorders is needed to address this important issue. (J Am Coll Cardiol
2009;53:221–31) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.042i
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cn the U.S., hormone therapy delivered as oral contracep-
ives (OCs) is one of the most commonly prescribed birth
ontrol methods, used by 11.6 million or 19% of women (1).
ince their introduction in the 1960s, OCs have been used
y approximately 80% of U.S. women at some point in their
ife to block ovulation, implantation, and, therefore, preg-
ancy (2). The simplicity of the available regimens, low
requency of side effects, and relative safety compared with
regnancy (3) has resulted in widespread use.
Observational studies demonstrate that young women
ave a relatively lower age-adjusted risk of cardiovascular
isease compared with men. Cardiovascular risk rises after
enopause (4), suggesting that endogenous reproductive
ormones may play a protective role. We and others have
urther demonstrated that disruption of ovulatory cycling,
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008, accepted September 30, 2008.ndicated by estrogen deficiency and hypothalamic dysfunc-
ion (5), or irregular menstrual cycling (6,7) in pre-
enopausal women is associated with an increased risk of
oronary atherosclerosis and adverse cardiovascular events,
espectively. The concept that pre-menopausal contracep-
ive hormone use may be protective for atherosclerosis is
ppealing.
Conversely, recently published data on mortality from
ardiovascular disease has shown that since the year 2000,
ortality rates have increased in women between the ages of
5 and 44 years compared with decreases in all other age
roups (4). Increased rates of obesity and smoking and
eclines in physical activity are prevalent in this group of
idlife women (8). Also coincident in this age group was an
ncreased OC use during the same decades, from 4% to 17%
1,2). In part because OCs are effective and safe for contracep-
ion, and because pre-menopausal women are at relatively
ower cardiovascular risk than the general public, there has
een relatively little specific study devoted to evaluating
inks between contraceptive hormone use and cardiovascular
isease.
Data from the Women’s Health Initiative that demon-
trated an increased cardiovascular risk with menopausal
ormone therapy use among women without pre-existing
ardiovascular disease (9–11) have prompted a review of risks
nd benefits of other forms of hormone therapy for women.
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Contraceptive Hormone Use and CVD January 20, 2009:221–31This review outlines the physiol-
ogy and mechanisms of cardio-
vascular action of contraceptive
hormones, particularly those
found in OCs. It includes basic
science, animal and human clin-
ical studies that address contra-
ceptive hormone use and cardio-
vascular disease. We also review
the current guidelines for contra-
ceptive hormone use in women
with elevated cardiovascular risk.
Estrogen and
Progesterone Physiology
Endogenous estrogen is pro-
duced by the ovaries in the form
of 17-estradiol, which acts at
estrogen receptors (ERs), ER and ER, with equal
inding affinity (12–14). There are 2 known pathways
riggered by estrogen activation of these receptors, com-
only referred to as the genomic and nongenomic
athways. The genomic pathway occurs through ligand
inding, in which estrogen as a steroid passes through the
ipid membrane and binds receptors located in the
ucleus, which either activates or suppresses gene tran-
criptions. The nongenomic pathway is a rapid activation
f the receptor located at the cell membrane and causes a
elease of intracellular messengers such as nitric oxide,
alcium, or kinases. For example, the nongenomic path-
ay results in activation of nitric oxide synthase to cause
cute arterial vasodilation (15,16).
Endogenous progesterone blood levels rise each month
rom the corpus leutem after ovulation, remain high
uring the luteal menstrual phase to inhibit ovulation,
nd eventually drop at the time of menstruation (17).
rogestins are the synthetic form of the hormone pro-
esterone derived from 19-nortestosterone, 17-OH pro-
esterone derivatives, or 19-norprogesterone (18). Bio-
dentical progesterone is used for menopausal therapy but
ot for contraception. There are many types of progestins,
ach differing in its potency and affinity to the progesterone,
strogen, and androgen receptors. Levonorgestrel (LNG)
nd norethindrone directly bind to the receptor while
esogestrol needs to be actively converted in the body before
eing bioavailable (17). The newer progestins, including
estodene, desogestrel, and norgestimate, are selective in
hat they have little androgenic effect while inhibiting
vulation and endometrial hypertrophy. The newest contra-
eptive and menopausal hormone formulations include
ombinations of estrogen and drospirenone, where the
rogestin is derived from spironolactone and has antiandro-
Abbreviations
and Acronyms
ACOG  American College
of Obstetrician and
Gynecologists
CI  confidence interval
EE  ethinyl estradiol
ER  estrogen receptor
HDL-C  high-density
lipoprotein cholesterol
LDL-C  low-density
lipoprotein cholesterol
LNG  levonorgestrel
MI  myocardial infarction
OC  oral contraceptive
RR  risk ratio
VTE  venous
thromboembolismenic and diuretic properties (19). lontraceptive Hormones: Initiation and Evolution
ontraceptive hormones were first introduced in the
960s as OCs that simulated a state of pregnancy by
ausing high hormonal blood levels that suppressed
vulation and implantation. The “pill” was developed to
e cyclical, with a 28-day cycle of 3 weeks of continuous
ombined fixed-dose estrogen and progestin followed by
week of sham pills. This design induced hormonal
ithdrawal bleeding to simulate the monthly menses and
eassure women of the absence of pregnancy.
There have been 3 main evolutions in OC develop-
ent, including changes to: 1) the dose and types of
ormones used; 2) the formulation timing and dosing;
nd 3) the delivery method. Doses of contraceptive
ormones have decreased considerably since the 1960s,
ith initial OCs containing relatively high doses of both
strogen and progestin. While first-generation estrogen
osages started at 150 g, second-generation dosages
ecreased to 50 g, and current-generation doses are now
ven lower, ranging from 20 to 35 g of ethinyl estradiol
EE) (20). Contemporary OCs remain at fairly high
strogen doses in contrast to menopausal hormone ther-
py, which typically contains one-tenth the dose or the
quivalent of 2.5 to 5 g of EE.
Contraceptive hormone formulation timing and dosing
lso varies. Table 1 outlines current hormonal contraceptive
ormulations available in the U.S. Monophasic dosing
onsists of doses that do not vary throughout the entire
onth, while in tricyclic dosing, the progestin portion of
he contraceptive hormone increases each week to mimic
he natural hormonal cycling in a woman. While many OCs
re still taken for 21 days with a 7-day sham pill or no
reatment phase, continuous dosing formulations of OCs
hat produce 4 menses/year and a continuous monophasic
ow-dose formulation that is taken 365 days/year with
irtually absent menses have been approved (21).
OCs are classified into generations (first, second, and
hird), depending upon their introduction into the U.S.
arket, and vary according to their dose of estrogen and
ype of progestin used. The first-generation OCs used
rogestins called “estranes,” such as norethindrone,
orethindrone-acetate, or ethynodiol diacetate. This gener-
tion of OCs contained 2 to 5 times the dose of estrogens
nd up to 10 times the dose of progestins compared with
ater generations (22). All subsequent-generation OCs con-
ained 50 g estrogen and varied by the type of progestin
sed. The second generation used progestins called “go-
anes,” which are more potent and allowed the use of lower
oses to produce an anovulatory effect. Examples include
NG or norgestimate. Third-generation OCs are also
onane progestins, such as desogestrol or gestondene, and
ave reduced androgenic and metabolic side effects. Most
ecently available are 2 nontestosterone-derived proges-
ins, chlormadinone acetate and drospirenone, which may
ead to a fourth-generation classification. Drospirenone is
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January 20, 2009:221–31 Contraceptive Hormone Use and CVDn aldosterone antagonist with antiandrogenic and di-
retic effects (19).
Contraceptive hormones also vary according to the method
f delivery and now include nonoral routes such as the
ombined estrogen/progestin transdermal patch and vaginal
ing. The transdermal patch or vaginal ring is worn continu-
usly for 21 days and removed for 7 days and delivers a
verview of Hormonal Contraception Formulations Available in U.S.
Table 1 Overview of Hormonal Contraception Formulations Ava
Dose
Oral Tripha
Estrogen/progestin*
Ethinyl estradiol/desogestrel 25 g/0.1, 0.125, 0.15 mg
Ethinyl estradiol/levonorgestrel 30 g/0.05 mg, 40 g/0.075 mg,
Ethinyl estradiol/norgestimate 25 g/0.18, 0.215, 0.25 mg
35 g/0.18, 0.215, 0.25 mg
Ethinyl estradiol/norethindrone 35 g/0.5, 0.75, 1 mg
35 g/0.5, 1, 0.5 mg
Oral Monoph
Estrogen/progestin‡
Ethinyl 20 g/0.09 mg
Estradiol/levonorgestrel 20 g/0.1 mg
30 g/0.15 mg
30 g/0.15 mg, 10 g/0 mg
Ethinyl estradiol/desogestrel 30 g/0.15 mg
Ethinyl Estradiol/norethindrone 20 g/1 mg
30 g/1.5 mg
35 g/0.4 mg
35 g/0.5 mg
35 g/1 mg
50 g/1 mg
Ethinyl estradiol/norgestrel 30 g/0.3 mg
Ethinyl estradiol/norgestimate 35 g/0.25 mg
Mestranol/norethindrone 50 g/1 mg
Ethinyl estradiol/drospirenone 20 g/3 mg
30 g/3 mg
Ethinyl estradiol/ethynodiol 35 g/1 mg
50 g/1 mg
Ethinyl estradiol/desogestrel 30 g/0.15 mg
Nonoral Comb
Transdermal estrogen/progestin
Ethinyl estradiol/norelgestromin 20 g/0.15 mg/day patch
Vaginal ring estrogen/progestin
Ethinyl estradiol/etonogestrel vaginal 15 g/0.12 mg/day vaginal ring
Prog
Oral progestin only
Norethindrone 0.35 mg
Progestin injection
Medroxyprogesterone acetate 150 mg, intramuscular, every 3 mo
104 mg, subcutaneous, every 3 mo
Progestin-releasing IUD
Levonorgestrel 52 mg IUD, daily release 20 g
or manufacturer information for all drugs, please see the Online Appendix. *21 active tablets an
oses, 9 tablet doses followed by 5 tablet doses; ‡21 active tablets and 7 placebo, active tablets are
r 10 g estradiol; 24 active tablets and 4 placebo.
IUD  intrauterine device.ontinuous estrogen and progestin formulation. Both of these iethods avoid first-pass metabolism in the liver, provide
ontinuous hormone dosing, and simplify compliance (23–25).
echanisms of Estrogen and
rogestin Action on the Cardiovascular System
Rs are found throughout the body in essentially all tissues
8
in U.S. 2008
Brand/Trade Name
rmulation
Cyclessa
/0.125 mg Enpresse, Trivora
Ortho Tri-Cyclen Lo
Ortho Tri-Cyclen, Tri-Previfem, Tri-Sprintec, TriNessa
Necon 7/7/7, Ortho-Novum 7/7/7
Aranelle, Tri-Norinyl†
ormulation
Lybrel
Alesse, Aviane, Lutera
Jolessa, Levora, Nordette, Portia, Quasense, Seasonale‡
Seasonique§
Apri, Desogen, Reclipsen
Junel 21 1/20, Loestrin 21 1/20,
Loestrin 24 Fe 1/20, Microgestin 1/20, Microgestin Fe 1/20
Junel 21 1.5/30, Loestrin 21 1.5/30,
Loestrin Fe 1.5/30, Microgestin 1.5/30, Microgestin Fe 1.5/30
Balziva, Femcom Fe, Ovcon 35
Brevicon, Modicon, Necon 0.5/35
Necon 1/35, Norinyl 1/35, Ortho-Novum 1/35
Necon 1/50, Ovcon 50
Cryselle, Lo/Ovral, Low-Ogestrel
MonoNessa, Ortho-Cyclen, Previfem, Sprintec
Norinyl 1/50
Yaz
Ocella, Yasmin
Kelnor, Zovia 1/35
Zovia 1/50
Ortho-Cept
ormulations
Ortho Evra
NuvaRing
nly
Camila, Errin, Jolivette, Nor-QD, OrthoMicronor, Ovrette
Depo-Provera
Depo-SubQ Provera
Mirena
ebo, active tablets divided into 7 tablet doses as indicated; †active pills are divided into 7 tablet
e dose; §91-day extended formulation available with 84 consecutive active tablets and 7 placebo200
ilable
sic Fo
30 g
asic F
ined F
estin O
nths
nths
d 7 plac
all samn both women and men and play an important role in
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Contraceptive Hormone Use and CVD January 20, 2009:221–31ealth and disease. In animal models, estrogen administra-
ion directly prevents atherosclerosis (12). Specific pathways
o the cardiovascular system include activation of the ER
eceptor on endothelial and myocardial cells that have
ntioxidant effects and improved endothelial cell injury
ecovery (12). ERs in the cardiovascular system modulate a
apid vasodilatory response via nitric oxide and also have
ong-term effects via the genomic pathway by increasing
ndothelial cell growth and inhibiting smooth muscle cell
roliferation. Estrogen reduces low-density lipoprotein cho-
esterol (LDL-C) oxidation and binding and platelet aggre-
ation, and increases cyclooxygenase-2 activity (12). There
s relatively less known regarding cardiovascular actions of
rogesterone and progestins.
ipoproteins. Estrogen also affects the cardiovascular sys-
em indirectly through its impact on cardiovascular risk
actors such as the lipid profile. OCs alter the lipid profile
ia the genomic pathway, in which ER alterations affect
epatic apolipoprotein up-regulation (12,26,27). Studies in
re-menopausal women using OCs have shown a dose-
elated response in the lipid profile. Women using a 20-g
E/100-g LNG OC demonstrated reductions in high-
ensity lipoprotein cholesterol (HDL-C) and small in-
reases in LDL-C and triglycerides, in contrast to a 30-g
E/150-g LNG OC (28). The amount of lipid alteration
lso depends on the delivery route, where transdermal
ontraceptive hormone delivery is relatively less potent
ompared with oral (12,29). Barkfeldt et al. (30) conducted
randomized, double-blind study that evaluated the effects
f lipid metabolism on 98 women who received 2 different
ypes of progestin-only pills, desogestrel 75 g/day or LNG
0 g/day. There were minimal changes seen to the lipid
rofile except for decreasing trends with levels of HDL-C,
ts subfractions, and the apolipoproteins apolipoprotein-I
nd -II. No differences were observed between the 2
ormulations despite the higher progestin dose found
n desogestrel, including no changes in LDL-C or
polipoprotein-B (30).
lood pressure. Most studies on blood pressure in normo-
ensive women have shown an increase in blood pressure
ssociated with OC use (31). A review of 2 studies found an
ncrease in systolic blood pressure by 7 to 8 mm Hg on
verage compared with systolic blood pressure in those not
sing OCs (32,33). The newer progestins such as dro-
pirenone, with antimineralocorticoid diuretic effects, pro-
uce lower blood pressure. In a study of 120 women
andomized to drospirenone/EE or LNG/EE, the dro-
pirenone group demonstrated a mean decrease in the
ystolic blood pressure (from 107.4 to 103.5 mm Hg), and
ad a statistically significant lower group mean blood
ressure compared with the LNG group (34). Another
tudy of 80 healthy women randomized into groups of 3 mg
f drospirenone combined with a 30-, 20-, or 15-g dose of
Es found that systolic blood pressure at 6 months fell by a
ange of 1 to 4 mm Hg across the groups, compared with an
levation of blood pressure of 4 mmHg in the control group rf LNG/EEs (35). Additionally, body weight fell by a range
f 0.8 to 1.7 kg in the groups receiving the drospirenone
ompared with an increase in the LNG/EE group by 0.7 kg.
lucose tolerance and diabetes mellitus. Contraceptive
ormones can also impact glucose tolerance and diabetes
ellitus. Oelkers et al. (35) studied glucose levels in 80
ealthy women assigned to 4 equal groups who received 3
g of drospirenone combined with 30-, 20-, and 15-g
oses of EE or LNG/30-g EE. Each woman performed
ral glucose tolerance tests at pre-treatment and at the end
f the 6-month OC cycle. On treatment, fasting glucose
as unchanged for all groups, but the area under the curve
or the glucose tolerance increased for all formulations.
lthough not statistically significant between groups, the
rospirenone/30-g EE group had a 19% worsening of
lucose tolerance (35). Available evidence with the earlier
eneration OCs demonstrates no apparent worsening of
stablished diabetes (36,37).
ovel risk factors. Estrogen use in menopausal women
levates inflammatory markers such as C-reactive protein
38,39), although it is unclear if this is a specific adverse
ardiovascular effect or a nonspecific up-regulation of he-
atic protein synthesis. Elevations in high-sensitivity
-reactive protein have also been found in third-generation
C users containing desogestrel or gestodene. A case-
ontrol study of healthy women found high-risk levels of
igh-sensitivity C-reactive protein (3 to 10 mg/l) in 27% of
C users compared with 8.5% of non-OC users (odds ratio:
.04, 95% confidence interval [CI]: 1.99 to 8.18) (40).
here is little known regarding hormonal contraception use
nd other novel risk factors such as homocysteine, uric acid,
nd other inflammatory markers.
There are additional hormonal pathways that may impact
ardiovascular disease. The dose of EE in OCs sustains
elatively higher blood levels of estrogen than the ovaries in
omen with normal ovulatory cycling and ensures adequate
strogen levels in women with ovulatory dysfunction/
strogen deficiency. Prior work demonstrates that up to 33%
f pre-menopausal women can have ovulatory dysfunction
nd estrogen deficiency and that this is associated with an
ncreased osteoporosis risk (41). Recent work from the
urses’ Health Study has documented a positive association
etween a history of irregular menstrual cycling and adverse
ardiovascular events (6), suggesting that ovulatory dysfunc-
ion and relatively low estrogen levels may also elevate
ardiovascular risk. Contraceptive hormones also suppress
varian androgens and raise sex hormone binding globulin,
hus reducing the free fraction of plasma testosterone. This
s a useful mechanism of action of OCs in women with
olycystic ovary syndrome and hyperandrogenemia, a con-
ition that may be associated with elevated cardiovascular
isk (42). Finally, contraceptive hormones appear to blunt
he adverse adrenocorticol stress response in primates,
hich might also offer indirect protection from atheroscle-
osis via neuroendodrine pathways (43).
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January 20, 2009:221–31 Contraceptive Hormone Use and CVDhrombosis. Estrogen has been known to have prothrom-
otic effects and elevates cardiovascular venous thromboem-
olism (VTE) risk by increasing prothrombin and decreas-
ng antithrombin III (14). In a large, matched case-control
tudy, Sidney et al. (44) found that OC use with 50-g
E correlated with a 4 times higher risk of VTE compared
ith that seen in nonusers (95% CI: 2.77 to 4.00). Jick et al.
45) studied the risk of nonfatal VTE in a case-control study
f low-dose estrogen 35 g plus second-generation
LNG) or third-generation (desogestrel or gestodene) pro-
estins and found that after adjusting for smoking and body
ass index, third-generation progestins had a 2-fold higher
isk ratio (RR) compared with second-generation progestins
or nonfatal VTE. It was also noted that the increased risk
ssociated with newer OC formulations was seen in the
omen who used OCs for6 months compared with those
ho use OCs for longer periods of time, although the
ifference was not statistically significant.
oronary vasomotion. Numerous clinical observations
upport the role of these reproductive hormones on regula-
ion of vasomotor tone. Migraine headaches, Raynaud’s
isease, and Prinzmetal’s angina are more common in
omen than men and can vary according to endogenous or
xogenous reproductive hormones (46,47). While animal
nd human work demonstrates that low endogenous estro-
en levels exacerbate endothelial dysfunction (48,49) and
hat estrogen replacement abolishes this effect (48,50,51),
he data are mixed with regard to whether long-term
strogen therapy maintains or improves coronary or periph-
ral endothelial function in humans (51). Even less is known
egarding progesterone, progestins, and androgens. Primate
tudy has demonstrated a coronary vasoconstrictive effect
ith medroxyprogesterone that was not apparent with
rogesterone (52,53). More clinical work is needed.
rrhythmogenesis. Women face a life-long higher risk of
udden cardiac death associated with electrocardiographic
T prolongation compared with men (54), and this is
articularly apparent in the post-adolescence years. Andro-
ens have been demonstrated to blunt QT prolongation in
esponse to quinidine (55), in contrast to estrogens that
odify the expression of potassium channels (56). Other
nvestigators have demonstrated that the 9-month post-
artum period has a significantly increased risk of cardiac
vents among women who are long QT genotype carriers
57). In healthy post-menopausal women, hormone replace-
ent therapy with estrogen alone usually produces a pro-
ongation of the QT interval, while estrogen plus proges-
erone had no significant effects on the QT interval but
educed QT dispersion; however, there are conflicting data
eported (58,59). Further work is needed to understand the
asis of gender differences in ventricular repolarization and
rrhythmogenic etiologies of cardiac death. In particular, no
tudy has been directed at the impact of contraceptive
ormones and susceptibility to drug-induced QT interval
rolongation and drug-induced arrhythmia that is rela-
ively more prevalent in women. Figure 1 depicts the Anown mechanisms whereby contraceptive hormones im-
act the cardiovascular system including effects on ath-
rosclerosis, thrombosis, vasomotion, and arrhythmogen-
sis (12,14,28–37,43,52,53,60,61).
ontraceptive Hormone
se and Cardiovascular Disease
nimal studies. Stress-induced interruption of the hypo-
halamic signaling of the ovary, resulting in anovulation and
ypoestrogenemia in primates, produces pre-menopausal
therosclerosis in the primate model (47,62,63), and provi-
ion of hormone contraception has been demonstrated to
lock this atherosclerotic effect (63,64). The use of a
rimate model of pre-menopausal oophorectomy and
enopausal hormone therapy demonstrates similar antiath-
rosclerotic effects (65).
Adams et al. (66) studied nonhuman primate models in
ynomolgus macaques to determine the effect of OCs on
ipoproteins and atherosclerosis. This design compared
lacebo with 2 different formulations of OCs over 24
onths. Despite both OC preparations reducing plasma
DL-C, both had a 50% to 75% decrease in the extent of
therosclerosis compared with that seen in placebo. This
tudy was further stratified by high-risk status, defined by
otal cholesterol/HDL-C ratio 4.5, and found a relatively
reater decrease of atherosclerosis by 75% to 85% in the
igh-risk group (66).
A second study in cynomolgus macaques was designed to
urther assess the impact of separate or combined effects of
strogen and progestin in low-dose OC preparations on
therosclerosis progression. This study randomized the
onkeys to receive triphasic combined EE/LNG, triphasic
E alone, LNG alone, or a placebo. All groups were treated
or a 25-month period and continued on a proatherogenic
iet. Results showed that among the animals treated with
E alone compared with untreated animals, atherosclerosis
as reduced by 67% (p  0.05), while the combination
E/LNG group had a 28% decrease in atherosclerosis, and
he LNG alone group had no effect (67). Further lipid
valuation demonstrated LDL-C particles that were smaller
nd less esterified in the EE alone or EE/LNG groups.
linical Studies
urrent and immediate past contraceptive hormone use in
ounger and midlife women. The Nurses’ Health Study,
nitiated in 1976, was an 8-year self-report prospective study
hat assessed the risk of myocardial infarction (MI) and OC
se in midlife women (ages 30 to 55 years). This study
ound no increased risk among past users of OCs for
ardiovascular disease, nonfatal MI, or fatal coronary disease
hen compared with those who had never used OCs (68).
dditionally, there was no association between the duration
f use and cardiovascular disease; women who had used
Cs for more than 10 years had no alteration in risk.
mong current OC users, however, there was a 2.5 relative
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Contraceptive Hormone Use and CVD January 20, 2009:221–31ncreased risk of adverse cardiovascular events, including
ardiovascular death, nonfatal MI, and stroke (68). The
ncrease in cardiovascular deaths and nonfatal MI and stroke in
urrent users but not with past use was believed to be associated
ith the prothrombotic effects, and 7 of 10 of the adverse
ardiovascular events occurred in current cigarette smokers
68). Stopping OCs was associated with a decline in the risk
or adverse cardiovascular events, with an RR of 0.95 (95% CI:
.81 to 1.11) among past users, suggestive of reversal of the
C prothrombotic effects with cessation of use; however, other
echanisms such as an antiatherosclerotic effect could also be
ontributory.
Other prospective studies consistently show an increased
Figure 1 Impact of Hormonal Contraception on Mechanisms of
Estrogens’ and progestins’ individual effects on atherosclerosis, thrombosis, vaso
ery route of estrogen; **dependent on type of progestin; ***dependent on the do
density lipoprotein; VSMC  vascular smooth muscle cell. Figure illustration by Roisk of acute MI among women who concomitantly use 2Cs and smoke, and extend the observation to past smokers
n OCs (68–71). Notably, these studies evaluated OC
redominantly with prior-generation OCs with the rela-
ively higher estrogen doses compared with those currently
sed. No studies to date have specifically evaluated the
ewer fourth-generation as well as the non-OC hormone
reparations with regard to current and immediate past
se-associated adverse cardiovascular events.
Two separate case-control studies evaluated the associa-
ion between OC use and MI, based on the second- and
hird-generation preparations with differing progestins and
eached varying conclusions. Dunn et al. (72) performed a
ommunity-based case-control study of 2,176 women over a
iovascular Disease
, and arrhythmogenesis (12,14,28–37,43,52,53,60,61). *Dependent on deliv-
estrogen. Cox-2  cyclooxygenase-2; HDL  high-density lipoprotein; LDL  low-
ell.Card
motion
se of
b Flew-year period and found a lower RR of 1.78 (95% CI: 0.66
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January 20, 2009:221–31 Contraceptive Hormone Use and CVDo 4.83) for MI with third-generation OCs compared with
econd-generation OC use (Table 2). In this study, third-
eneration OCs were defined as the progestins gestodene or
esogestrel combined with EE compared with second-
eneration OCs defined as LNG and noresthisterone com-
ined with 50 g of EE. Tanis et al. (73) performed a
ase-control study of 1,173 women over 6 years and con-
luded that the use of second-generation OCs, containing
NG, increased the risk of MI by an RR of 2.3, while
hird-generation, containing desogestrel or gestodene, and
ther progestins such as cyproterone or norgestimate, did
ot significantly increase the risk (Table 2). Additionally,
his latter study analyzed subjects for the presence of
rothrombotic genetic mutations and concluded that there
as a nonsignificant increased risk in subjects with a Factor
Leiden or prothrombin mutation who used third-
eneration OCs (RR: 1.9, 95% CI: 0.6 to 5.5).
A recent prospective study from Sweden followed 48,321
omen age 30 to 49 years over an average of 11 years. The
tudy, which ended in 2002, was conducted to determine
he risk of MI associated with the use of OCs. During the
ollow-up period, there were 190 nonfatal MIs and 24
eaths due to MI. When adjusted for age as well as cardiac
isk factors such as hypertension, smoking status, and
iabetes, the study found no increased risk of MI in both
ormer and current users of OCs (Table 2). Additionally,
here was no increased risk of MI in women with duration
f use of OCs stratified to over 15 years (RR: 0.7, 95% CI:
.4 to 1.2) (2). Table 2 summarizes these cardiovascular risk
ata stratified according to first-, second-, and third-
eneration OC formulations (2,45,68,72–78).
onger-term prior contraceptive hormone use in post-
enopausal women. While it is clear that current OC use
s associated with an increased risk of MI in women with
re-existing risk factors such as cigarette smoking
69,72,79), insufficient prior data have existed with regard to
onger-term past OC use and subsequent cardiovascular
isease in the post-menopausal period. There is a relative
aucity of data due to: 1) the relatively short population
xposure time (OCs have only been available since the
960s); 2) the decades needed to perform clinical adverse
vent studies; and 3) the additional follow-up time needed
ue to the majority of cardiovascular disease events occur-
ing later in life among older women. Given the animal and
uman data consistent with antiatherosclerotic effects of
C, it is reasonable to hypothesize that, compared with
onusers, women with a history of OC use in their
re-menopausal years may be relatively protected against
therosclerosis, resulting in a relatively lower cardiovascular
isease burden during post-menopause.
Stampfer et al. (68) demonstrated a lower RR for adverse
oronary disease events of 0.8 (95% CI: 0.6 to 1.0) among
he past OC users compared with nonprior users in 119,061
omen followed for 8 years. While these results were
tatistically significant, there were relatively few adverse
oronary disease events in this population with an approx- Omate mean age of 63 years, and this analysis has not been
pdated. Similar results suggestive of a protective OC effect
ave been found in smaller studies evaluating adverse
ardiac events (80) and coronary angiography (81). A
uantitative meta-analysis of 13 studies included in the
tampfer et al. (68) work provided an estimated RR
ssociated with past OC use of 1.01 (95% CI: 0.91 to 1.13),
esulting in their conclusion that past OC use had little or
o impact on subsequent cardiovascular disease (82).
One study has directly assessed this question using
uantitative measures of atherosclerosis. Past OC use and
vidence of atherosclerotic coronary artery disease was
ssessed in 672 post-menopausal women with coronary risk
actors and undergoing coronary angiography for suspected
schemia in the WISE (Women’s Ischemia Syndrome
valuation) study (83). Past OC hormone use was associ-
ted with a 2.4% reduced risk of atherosclerotic coronary
rtery disease measured by quantitative coronary analysis in
core laboratory despite adjustment for age and coronary
isk factors (Fig. 2). There was no apparent relation between
uration of past OC use and the coronary artery disease
everity index score, however. Limitations of this observa-
ional study included a greater use of menopausal hormone
herapy and a higher risk factor burden among the past users
f OCs, although these factors may have mitigated more
dverse cardiovascular events and atherosclerosis in this
roup, respectively.
urrent Hormonal Contraceptive
rescribing Guidelines for Women
t Elevated Cardiovascular Risk
he American College of Obstetrician and Gynecologists
ACOG) created guidelines for prescribing OCs in women
ith medical conditions, specifically addressing women with
ardiovascular risk factors such as hypertension, dyslipide-
ia, diabetes, smoking, and obesity (60). In addition,
COG addresses OC use in women older than 35 years of
ge. In women with pre-existing hypertension, who are
therwise healthy, OCs can be used if 35 years old and
lood pressure is well-controlled and monitored. If blood
ressure remains stable after a few months, then OC may be
ontinued. Current ACOG guidelines recommend pre-
reatment fasting lipid profiles in women who are dyslipi-
emic with monitoring once they have stabilized on an OC.
lternative nonhormonal contraceptive methods, such as an
ntrauterine device, should be used if the patient has an
DL-C 160 mg/dl or multiple cardiac risk factors. OC
se in diabetic women, either type I or II, is only appropriate
or use in otherwise healthy women younger than 35 years
ld. The ACOG cautions against prescribing OCs in
omen who smoke and are over the age of 35. Obesity is
elt to be an independent risk factor for VTE; therefore, the
uideline recommends alternate nonhormonal contraceptive
ethods. Finally, for women older than 35 years of age,
Cs with 50 g EE remain safer than pregnancy in
Observational Clinical Studies of Risk of CVD Events in Women With Current Contraceptive Hormone Use
Table 2 Observational Clinical Studies of Risk of CVD Events in Women With Current Contraceptive Hormone Use
Authors, Year (Ref. #) OC Generation Definitions n CVD Definition Follow-Up (yrs)
RR (Unless Stated,
Compared With Nonusers)
95% Confidence
Interval
Stampfer et al., 1988 (68) No distinction made with OC generation Total 62,718
Cases 485
All cardiovascular deaths, nonfatal
MI, and CVAs
8 Past user 0.95
Current user 2.5
(0.81–1.11)*
(1.3–4.9)*
Jick et al., 1995 (45) Second generation: EE 35 g  LNG
Third generation: 35 g  gestodene
or desogestrel
Total 303,470
Cases 15
Death related to cardiovascular
cause: MI, CVA, PE, cardiac
arrest
3.8 Third-generation (desogestrel) users with
second generation as baseline 0.4
Third-generation (gestodene) users 1.4
(0.1–2.1)*
(0.5–4.5)*
WHO et al., 1996 (74) No distinction made with OC generation Total 1,309
Cases 368
Nonfatal first MI 5 Current users OR 5.01 in Europe
Current users OR 4.78 in developing
countries
Past users 10 yrs 1.61
(2.54–9.90)†
(2.52–9.07)†
(0.62–4.16)
Sidney et al., 1998 (77) No distinction made with OC generation
EE with 50 g and 50 g
Total 1,264
Cases 271
MI 3.25 OR for current OC users 0.56
OR for past OC users 0.54
(0.21–1.49)†
(0.31–0.95)†
Progestins with norethindrone and from
gonane family
Dunn et al., 1999 (72) Second generation: EE 50 g 
norethisterone or LNG
Third generation: EE 50 g 
gestodene or desogestrel
Total 2,176
Cases 448
MI 2 All combined OC users 1.4
Second-generation users 1.1
Third-generation users 1.96
Adjusted for third- versus second-generation
users 1.78
(0.78–2.52)†
(0.52–2.30)†
(0.87–4.39)†
(0.66–4.83)†
Dunn et al., 2001 (75) Second generation: EE 35 g 
norethisterone or LNG
Third generation: EE 35 g 
gestodene or desogestrel
Total 532
Cases 110
Fatal MI 2 Second-generation OC users 2.88
Third-generation OC users 0.83
(1.22–6.77)†
(0.25–2.81)†
Rosenberg et al., 2001 (76) No distinction made with OC generation
EE with 50, 35–49, 35 g
Progestin with norethindrone, LNG,
desogestrel, and norgestimate
Total 6,574
Cases 627
Nonfatal first MI 14 OR for current OC use 1.3
Current user OC by type found NS OR around
1 except those with norethindrone
(first generation) RR 2.5
(0.8–2.2)
(1.1–5.5)
Tanis et al., 2001 (73) First generation: EE 30 g 
lynestrenol
Second generation: EE 30 g  LNG
Third generation: EE 30 g 
desogestrel or gestodene, and other
progestins, cyproterone or
norgestimate
Total 1,173
Cases 248
MI 6 Past second-generation users 2.4
Current second-generation users 2.7
Past third-generation users 1.3
Current third-generation users 1.6
(1.6–3.6)†
(1.6–4.3)
(0.8–2.3)
(0.9–2.9)
Spitzer et al., 2002 (78) Second generation: EE 35 g 
norgestrel or LNG
Third generation: EE 35 g 
desogestrel or gestodene
Total 6,464 MI Meta-analysis 7
studies
OR for third-generation users 1.13
OR for second-generation users 2.18
OR for third- compared with second-
generation users 0.62
(0.66–1.92)
(1.62–2.94)
(0.38–0.99)
Margolis et al., 2007 (2) Second generation: EE 35 g 
norgestrel or LNG
Third generation: EE 35 g 
desogestrel
Total 48,321
Cases 214
MI 11 Past users 1.0*
Current users 0.7*
(0.7–1.4)†
(0.4–1.4)
*Age-adjusted relative risk (RR); †adjusted for cardiac risk factors: age, body mass index, smoking status, alcohol intake, physical activity, hypertension, diabetes, menopausal status; see text for specific adjusted risk factors.
CVA  stroke; CVD  cardiovascular disease; EE  ethinyl estradiol; LNG  levonorgestrel; MI  myocardial infarction; NS  nonsignificant; OC  oral contraceptive; OR  odds ratio; PE  pulmonary embolism.
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January 20, 2009:221–31 Contraceptive Hormone Use and CVDealthy, nonsmoking women, and can be continued until
ge 50 to 55 years or until menopause after reviewing risks
nd benefits. There are no guidelines for transitioning OCs
o menopausal hormone therapy; however, after the age of
0 years, measurement of follicle-stimulating hormone after
days off OCs to determine menopausal status can provide
uidance (84). There are no guidelines about the fourth-
eneration OCs to date; thus, prudent practice including
hese as well as the contraceptive transdermal patches is to
onsider them similar to the other available preparations
nd not as safer alternatives. Table 3 summarizes the
rescribing guidelines for hormonal contraceptives in
omen with elevated cardiovascular risk.
iscussion and Recommendations
variety of basic animal and human data suggest that
ontraceptive hormones have antiatherosclerotic effects;
owever, relatively less is known regarding the impact on
hrombosis, vasomotion, and arrhythmogenesis, mechanis-
ic pathways that also contribute to cardiovascular risk and
enefit. No carefully controlled trials with cardiovascular
isease end points exist to guide our practice regarding
ormonal contraception, which is used by over 80% of U.S.
omen at some point in their lifetimes.
Existing observational data with earlier first- and second-
eneration, higher-dosage OC formulations consistently
emonstrate small but significantly elevated risks of MI and
TE among current users, particularly smokers, while
iscontinuation or use of a third-generation formulation is
ssociated with a reduction/no elevation in risk. The highest
isk of thrombosis appears to occur within the first year of
se, appears to be linked with higher estrogen doses, and
mpacts a select group of women. Newer-generation formu-
ations currently in use indicate no increased MI risk for
urrent users, but a persistent increased risk of VTE that is
Figure 2
Coronary Artery Severity Score,
Assessed by Quantitative Coronary
Angiography, Stratified by Reported Prior OC Use
Past oral contraceptive (OC) hormone use was associated with a reduced risk
of atherosclerotic coronary artery disease. Reprinted, with permission, from
Merz et al. (83).imilarly time related.
B
lMeasurement of a fasting lipid panel is recommended in
omen with dyslipidemia before use of OCs, and alterna-
ive nonhormonal contraceptive should be sought if LDL-C
s not below 160 mg/dl. Measurement and monitoring of
lood pressure are also important to ensure that blood
ressure control is not compromised. Women age 35 years
nd older should be assessed for cardiovascular risk includ-
ng hypertension, smoking, diabetes, nephropathy, and
ther vascular diseases, including migraines, before OC use.
urrent World Health Organization and ACOG guide-
ines for women age 35 years and older recommend against
he use of OCs in women with these risk factors (3). OCs
ay be used in the perimenopausal transition, where higher
oses of estrogen are needed to suppress ovulation com-
ared with doses needed to treat menopausal symptoms
uch as hot flashes.
There are no cardiovascular data available for the newest
eneration contraceptive hormone formulations, including
he progestins that lower blood pressure and body weight, as
ell as the nonoral routes (transdermal and vaginal). While
hese newer formulations might be expected to have an
verall lower risk, specific study is needed. Current guide-
ines indicate that, as with all medication, contraceptive
ormones should be selected and initiated by weighing risks
nd benefits for the individual patient.
Existing data are mixed with regard to possible protection
rom early generation OCs for atherosclerosis; longer-term
ardiovascular follow-up of post-menopausal women with
egard to prior OC use, including subgroup information
egarding adequacy of ovulatory cycling, the presence of
yperandrogenic conditions, and the presence of prothrom-
ummary of Hormonalontraceptive Prescribing Guidelinesor Women With Elevated Car iovascular Risk
Table 3
Summary of Hormonal
Contraceptive Prescribing Guidelines
for Women With Elevated Cardiovascular Risk
Hypertension Well-controlled BP in women 35 yrs of age and
otherwise healthy, nonsmoking ¡ trial of OC.
Monitor BP and if controlled after starting, OC may be
continued.
If BP not well controlled, alternative methods such as
progestin-only pills or IUD may be started.
Dyslipidemia LDL-C 160 mg/dl or multiple cardiac risk factors ¡
alternative nonhormonal contraceptive methods, such
as an IUD.
Diabetes Diabetes type I or II, OC is only appropriate for use in
otherwise healthy, nonsmokers 35 yrs of age.
Otherwise progestin-only or IUD may be started.
Smoking Smoking and 35 yrs of age ¡ alternative nonhormonal
contraceptive methods, such as an IUD.
Smokers 35 yrs of age are not addressed.
Obesity Obesity (BMI 30 kg/m2) ¡ alternative nonhormonal
contraceptive methods such as progestin-only
contraception or IUD. Obesity is felt to be an
independent risk factor for VTE.
Women older than
35 yrs of age
Healthy, nonsmoking women ¡ OC with 50 g EE
remain safer than pregnancy, and can be continued
until 50 to 55 yrs of age or until menopause after
reviewing risks and benefits.MI  body mass index; BP  blood pressure; IUD  intrauterine device; LDL-C  low-density
ipoprotein cholesterol; VTE  venous thromboembolus; other abbreviations as in Table 2.
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ssue.
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APPENDIX
or a list of manufacturers for the drugs included in Table 1, please see the
nline version of this article.
